Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Model scores of the 29,894 trials active now.
Model score 27% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2017-04-25, after 2012-07-13 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-04-25. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: lymphomahodgkinlymphocyticleukemiacancer
Phrases that lowered it: bloodbodycordkgcriteria patients -
Sponsor's past termination rate: 28.5% (raises risk) · Sponsor's track record
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Phase: 1 (lowers risk) · Design
-
Collaborators: 2 (lowers risk) · Design
-
Disease area, cancer: Yes (raises risk) · Disease area
-
Trials the sponsor started in the prior 2 years: 159 (lowers risk) · Sponsor's track record
-
Sponsor's past trials: 354 (lowers risk) · Sponsor's track record
-
Design: single group (raises risk) · Design
-
Drug's FAERS reports with a death: 28.7% (raises risk) · Drug's FDA history
-
Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
-
Minimum age: 1 (lowers risk) · Who can join
-
Drug's FAERS reports in the prior 12 months: 12749 (lowers risk) · Drug's FDA history
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Primary purpose: treatment (raises risk) · Design
-
Maximum age: 80 (lowers risk) · Who can join
-
Has a data monitoring committee: No (lowers risk) · Design
-
Keywords listed: 44 (raises risk) · Design
-
Disease area, respiratory: Yes (raises risk) · Disease area
-
Responsible party: sponsor (lowers risk) · Design
-
Blinding: none (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1 (typical: 2)
- Number of arms
- 2
- Allocation
- non randomized (typical: randomized)
- Design
- single group (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 2 (typical: 0)
- Keywords listed
- 44 (typical: 1)
Who can join
- Minimum age
- 1 (typical: 18)
- Maximum age
- 80 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 354 (typical: 32)
- Sponsor's past termination rate
- 28.5% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 159 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 8 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 57854 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 12749 (typical: 412.5)
- Drug's FAERS reports marked serious
- 96.9% (typical: 85.6%)
- Drug's FAERS reports with a death
- 28.7% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer, respiratory, immunology, hematology
- Drugs matched to FDA substances
- busulfan, clofarabine, fludarabine, melphalan, mycophenolate mofetil, mycophenolic acid, rituximab, tacrolimus
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma NCT03096782 · started 2017 · scored riskier than 95% of active trials completed
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 · started 2008 · scored riskier than 61% of active trials completed
- Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer NCT00963872 · started 2010 · scored riskier than 99% of active trials terminated
- Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. NCT00739141 · started 2008 · scored riskier than 62% of active trials completed
- Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit NCT01050946 · started 2009 · scored riskier than 91% of active trials terminated
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.